Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

被引:74
|
作者
Reesink, Herre J. [1 ]
Surie, Sulaiman [1 ]
Kloek, Jaap J. [2 ]
Tan, Hanno L. [3 ]
Tepaske, Robert [4 ]
Fedullo, Peter F. [5 ]
Bresser, Paul [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Cardiothorac Surg, NL-1100 DE Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1100 DE Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1100 DE Amsterdam, Netherlands
[5] Univ Calif San Diego, Div Repiratory & Crit Care Med, San Diego, CA 92103 USA
来源
关键词
RIGHT-VENTRICULAR DYSFUNCTION; BRAIN NATRIURETIC PEPTIDE; THERAPY; SILDENAFIL; MORTALITY; MARKER;
D O I
10.1016/j.jtcvs.2009.03.053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In proximal chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy is the treatment of first choice. In general, medical treatment before pulmonary endarterectomy is not indicated. However, selected "high-risk" patients might benefit by optimization of pulmonary hemodynamics. Moreover, in patients whose surgery is delayed owing to limited medical resources, pretreatment may prevent clinical deterioration. The primary objective of this study was to determine whether the dual endothelin-1 antagonist bosentan improves pulmonary hemodynamics and functional capacity in patients with proximal chronic thromboembolic pulmonary hypertension waiting for pulmonary endarterectomy. Methods: We used an investigator-initiated, randomized, controlled single-blind study. Patients were randomized to receive bosentan (n = 13) or no bosentan (n = 12) for 16 weeks, next to "best standard of care." The primary end point was change in total pulmonary resistance. Secondary end points included changes in 6-minute walk distance, mean pulmonary artery pressure, and cardiac index. Results: After 16 weeks, the mean differences in change from baseline between the groups were as follows: total pulmonary resistance 299 dynes . s . cm(-5) (P = .004), 6-minute walk distance 33 m (P = .014), mean pulmonary artery pressure 11 mm Hg (P = .005), and cardiac index 0.3 L . min(-1) . m(-2) (P = .08). Treatment with bosentan was safe. After pulmonary endarterectomy, 4 patients died (no-bosentan group: n = 3); the short-term in-hospital postoperative clinical course was similar in both groups of patients. Conclusions: Patients with proximal chronic thromboembolic pulmonary hypertension may benefit hemodynamically and clinically from treatment with bosentan before pulmonary endarterectomy. Individual factors predictive of a beneficial response and whether this influences either morbidity or mortality associated with pulmonary endarterectomy remain to be established. (J Thorac Cardiovasc Surg 2010; 139: 85-91)
引用
收藏
页码:85 / 91
页数:7
相关论文
共 50 条
  • [1] Bosentan for chronic thromboembolic pulmonary hypertension
    Bonderman, D.
    Skoro-Sajer, N.
    Hitsch, R.
    Kneussl, M.
    Klepetko, W.
    Lang, I. M.
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 : 621 - 621
  • [2] Bosentan and chronic thromboembolic pulmonary hypertension
    Tomas, Cristina
    Callejas-Rubio, Jose Luis
    Rios-Fernandez, Raquel
    Ortego-Centeno, Norberto
    [J]. MEDICINA CLINICA, 2007, 129 (16): : 639 - 639
  • [3] Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
    Guth, S.
    Kramm, T.
    Wiedenroth, C.
    Mayer, E.
    [J]. ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE, 2014, 28 (03): : 178 - 183
  • [4] Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension
    Sunar, Hasan
    Yildizeli, Bedrettin
    Tas, Serpi
    Yanartas, Mehmet
    Sacli, Hakan
    Kis, Mahmut
    Cayhan, Burcin
    Kocak, Tuncer
    Kaymaz, Cihangir
    [J]. TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 21 (01): : 7 - 13
  • [5] Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension
    Balmer, Christian
    Jenkins, David P.
    Kern, Christian
    Vuylsteke, Alain
    [J]. ANESTHESIE & REANIMATION, 2016, 2 (01): : 35 - 56
  • [6] PULMONARY ENDARTERECTOMY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
    Iqbal, Tahir
    Jan, Azam
    Ahmed, Naseer
    Muhammad, Amir
    Shah, Sayed Mumtaz
    Khan, Sajid
    Tahir, Imran
    Shah, Husain
    Iftikhar, Nabil
    Jamil-ur-Rehman
    [J]. PAKISTAN HEART JOURNAL, 2021, 54 (02): : 126 - 131
  • [7] Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension
    Lankeit, Mareike
    Krieg, Valentin
    Hobohm, Lukas
    Koelmel, Sebastian
    Liebetrau, Christoph
    Konstantinides, Stavros
    Hamm, Christian W.
    Mayer, Eckhard
    Wiedenroth, Christoph B.
    Guth, Stefan
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (02): : 250 - 258
  • [8] Effects of sildenafil as a bridge therapy for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension
    Fukui, Shigefumi
    Palazzini, Massimiliano
    Gotti, Enrico
    Pacini, Davide
    Suarez, Sofia
    Ogo, Takeshi
    Yasuda, Satoshi
    Manes, Alessandra
    Nakanishi, Norifumi
    Galie, Nazzareno
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [9] Bosentan therapy for chronic thromboembolic pulmonary hypertension
    Ulrich, Silvia
    Speich, Rudolf
    Domenighetti, Guido
    Geiser, Thomas
    Aubert, John-David
    Rochat, Thierry
    Huber, Lars
    Treder, Ursula
    Fischler, Manuel
    [J]. SWISS MEDICAL WEEKLY, 2007, 137 (41-42) : 573 - 580
  • [10] Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension
    D'Armini, Andrea M.
    Morsolini, Marco
    Mattiucci, Gabriella
    Grazioli, Valentina
    Pin, Maurizio
    Valentini, Adele
    Silvaggio, Giuseppe
    Klersy, Catherine
    Dore, Roberto
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2014, 148 (03): : 1005 - 1011